Antrodia cinnamomea for Liver Health

Verdict: Published with Warning

Across 4 PubMed studies, the evidence for Antrodia cinnamomea in Liver Health grades Tier C — weak evidence. Effective, but with safety or population caveats.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.54

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Published with Warning

Confidence

47%

Conflicting evidence

Evidence level

Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive

L1 ExamineGlobal benchmark

0.50

L5 Clinical bodiesAuthoritative stance

0.50

L11 AI re-checkIndependent read

0.50

L2 PubMedPrimary literature

0.60

L3 MechanismPlausibility

0.65

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.539
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Comparative Efficacy of Antrodia cinnamomea on Liver Function Biomarkers in Mice and Rats: A Network Meta-Analysis

PMID: 40563294 2025 統合分析 n = 15

Finding: High-dose triterpenoids most effectively reduced ALT (MD: -42.37 U/L) and were most robust across biomarkers; medium-dose triterpenoids gave greatest AST reduction (MD: -50.18 U/L).

Academic Effect size: MD ALT -42.37 U/L; MD AST -50.18 U/L (animal models)

View on PubMed

Clinical Benefits of Golden-Antrodia Camphorata Containing Antroquinonol in Liver Protection and Liver Fat Reduction After Alcoholic Hepatitis

PMID: 35800453 2022 RCT (open-label) n = 80

Finding: AST declined significantly (p<0.0001), ALT declined (p=0.0002), triglycerides declined (p=0.0158) vs placebo over 12 weeks.

🟠 Limited quality ⚠️ Industry-funded

View on PubMed

Hepatoprotective effect of Antrodia Cinnamomea mycelia extract in subhealth Japanese adults: a randomized, double-blind, placebo-controlled clinical study

PMID: 36476310 2023 RCT (double-blind) n = 44

Finding: No significant change in ALT/AST in full cohort; subgroup of regular drinkers (>2x/week) showed significant ALT improvement vs placebo (p-value not reported in abstract).

⚠️ Industry-funded

View on PubMed

Hepatoprotective Effect of Antrodia camphorata Mycelium Powder on Alcohol-Induced Liver Damage

PMID: 39408373 2024 Animal Study n = 60

Finding: Significantly reduced liver enzymes and inflammation across dose groups; comparable to silymarin (specific p-values not in abstract).

🟠 Limited quality ⚠️ Industry-funded

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

cancer fighting properties source↗

L4b EU EFSA

Cautious

The Panel concludes that the NF, freeze-dried mycelia of Antrodia camphorata, is safe at the proposed use level for individuals aged 14 years and above. ... maximum dose of 990 mg per day ... in food supplements as defined in Directive 2002/46/EC ... for the general population. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬4 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-antrodia-cinnamomea-001 繁體中文版 →